Israeli Startup Kailo Pharma Pioneers Novel Approach to PTSD Treatment
A groundbreaking discovery from the University of Haifa is poised to redefine the treatment of Post-Traumatic Stress Disorder (PTSD). Israeli startup Kailo Pharma has secured NIS 6.5 million (approximately $2.1 million) in funding to develop a first-of-its-kind drug targeting the core mechanisms of traumatic memory, rather than simply managing symptoms.
The Problem with Current PTSD Treatments
Existing PTSD treatments largely rely on psychiatric medications and psychological therapies aimed at alleviating symptoms like anxiety, depression, and flashbacks. Although these approaches can be helpful, they don’t address the underlying neurological processes that perpetuate the disorder. The global PTSD population is estimated at around 300 million people, highlighting the urgent need for more effective interventions.
Unlocking the Brain’s Trauma Mechanism
Researchers Dr. Iris Reuveni and Prof. Edi Barkai at the University of Haifa have identified a previously unknown brain mechanism responsible for the “amplification” of fear memories. This amplification process isn’t present in normal memory formation. Instead of a typical strengthening of synaptic connections, traumatic memories trigger a widespread alteration across all synaptic connections of affected neurons.
This amplified signal is believed to be the root cause of debilitating symptoms like flashbacks and nightmares, and explains why traumatic memories can persist for years, even decades.
A Peptide-Based Solution: Nasal Spray Delivery
Working with Prof. Chaim Gillon of the Hebrew University, the team is developing a peptide – a short chain of amino acids – designed to neutralize this amplification mechanism. The proposed treatment will be administered as a nasal spray, allowing the peptide to directly reach the central nervous system.
Unlike some memory-focused therapies, this approach aims to reduce the intensity of the trauma without erasing the memory itself. This is crucial, as complete memory erasure carries risks of unintended consequences and may hinder effective processing of the traumatic experience.
Why This Approach is Different
Other attempts to erase memories can potentially damage non-traumatic memories or create fragmented recall. Many of these approaches require intervention shortly after the traumatic event. Kailo Pharma’s method, by targeting the amplification mechanism, could remain effective even long after the trauma occurred.
“Developing a specific peptide that can be administered as a spray is a significant advantage over competitors who offer treatment for symptoms only,” says Dr. Osnat On, CEO of Kailo Pharma.
Timeline and Future Outlook
Kailo Pharma plans to conduct further trials in mice to refine dosage and validate results. Human clinical trials are anticipated to initiate in approximately three years, with potential commercialization within five to ten years, pending successful outcomes. The company is owned by the University of Haifa’s technology transfer company, Carmel, and the venture capital fund NGT Healthcare II, with funding support from the Israel Innovation Authority.
Frequently Asked Questions
What is a peptide?
Peptides are short chains of amino acids, which are the building blocks of proteins. They play a vital role in many biological processes.
How does this treatment differ from existing PTSD therapies?
Current therapies primarily manage symptoms. This treatment aims to address the underlying neurological mechanism responsible for the persistence of traumatic memories.
Will this treatment erase the memory of the trauma?
No. The goal is to reduce the intensity of the memory, allowing patients to process the experience more effectively, not to erase it completely.
When might this treatment be available to patients?
Human clinical trials are expected to begin in approximately three years, with potential commercialization within five to ten years.
What is the significance of nasal spray delivery?
Nasal spray delivery allows the peptide to reach the central nervous system directly, potentially increasing its effectiveness.
Learn more about the research at the University of Haifa.
Do you have experience with PTSD or know someone who does? Share your thoughts in the comments below.
